0.8350 +0.02 (2.64%)
After hours: 7:59PM EST
|Bid||0.8152 x 1200|
|Ask||0.8350 x 1100|
|Day's Range||0.8000 - 0.8500|
|52 Week Range||0.5500 - 3.6200|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||5.28|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.
In the midst of a dramatic start to December, market news has taken a backseat to a surge in volatility and reactionary trading. However, volatility doesn’t stop the headlines, and there’s still big catalysts ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
The Redwood City, California-based company said it had net income of 16 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Anyone researching OncoMed Pharmaceuticals Inc (NASDAQ:OMED) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...
OncoMed (OMED) delivered earnings and revenue surprises of 56.52% and -8.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 10 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...